%0 Case Reports
%T Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRASG12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report.
%A Stratton N
%A Thompson J
%J JTO Clin Res Rep
%V 5
%N 4
%D 2024 Apr
%M 38550295
暂无%R 10.1016/j.jtocrr.2024.100661
%X Both sotorasib and adagrasib are approved for use in metastatic KRASG12C-mutated NSCLC after cancer progression on chemotherapy and immunotherapy. Hepatoxicity is a commonly encountered adverse effect of both agents, and little data exists about the safety of sequential use of these agents when hepatotoxicity is encountered. In this case report, we describe a patient who developed recurrent hepatotoxicity with sotorasib and was able to switch to adagrasib without hepatotoxicity and subsequently experienced a prolonged cancer response. We also describe a previously unreported adagrasib adverse effect of photoinduced skin hyperpigmentation.